XGEN Venture
VC Fund
Milan, Italy
XGEN Venture is an Italian alternative investment fund manager (Società di Gestione del Risparmio, or SGR) with over 15 years of experience in the startup process and the development of innovative solutions for high unmet medical needs.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries XGEN Venture invests in
Stages XGEN Venture invests in
Countries XGEN Venture invests in
Round sizes
Round size
- Series A
- $11M–$98M
- Series B
- $4.6M–$141M
Investment Focus
Industry
- Biotechnology 6 (75%)
- Health Care 4 (50%)
- Therapeutics 3 (38%)
- Life Science 2 (25%)
- Pharmaceutical 2 (25%)
Stage
- Series B 4 (50%)
- Series A 3 (38%)
- Series C 1 (13%)
Country
- Italy 4 (50%)
- Sweden 1 (13%)
- Germany 1 (13%)
- Switzerland 1 (13%)
- United Kingdom 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EpilepsyGTx
|
EpilepsyGTx is a late-stage biotech company exploring cutting-edge gene therapies to improve the management of focal refractory epilepsy (FRE). | $33M / Series A / Dec 10, 2025 | |
AAVantgarde Bio
|
AAVantgarde Bio is developing gene therapies for inherited retinal disorders. | $141M / Series B / Nov 03, 2025 | |
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $4.6M / Series B / Oct 21, 2025 | |
NanoPhoria
|
NanoPhoria is a biotechnology company focused on the development of innovative cardiovascular treatments. It specializes in a non-viral, nano-in-micro delivery system for biologics, designed to target the heart directly. This preclinical stage company is exploring the potential of inhalable therapies, utilizing tissue-directed delivery methods fortherapeutic peptides and RNAs. NanoPhoria's approach aims to revolutionize the treatment of cardiovascular diseases by offering a versatile, non-viral drug delivery platform, formulated for both inhalation and other administration routes. With a dedicated team, NanoPhoria is committed to advancing cardiovascular health through groundbreaking research and development. | $97.8M / Series A / Oct 06, 2025 | |
Genespire
|
Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. | $52.2M / Series B / Sep 24, 2024 | |
TES Pharma
|
TES Pharma is a research-based biopharmaceutical company focusses on delivering first in class preclinical candidates that unlock the potential of novel therapeutic targets and mechanisms. | $10.7M / Series A / Apr 10, 2024 | |
Protembis
|
ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation. | $32.5M / Series B / Mar 26, 2024 | |
Nouscom
|
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.The NousCom team is lead by experiencedenterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies. | $73.4M / Series C / Nov 14, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does XGEN Venture invest in?
XGEN Venture invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is XGEN Venture's check size?
XGEN Venture typically joins rounds of $11M–$98M at Series A and $4.6M–$141M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds XGEN Venture participates in.
When did XGEN Venture last invest?
The most recent investment recorded for XGEN Venture closed in Dec 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
